Li Qin, Xiong Chunmei, Liu Hongli, Ge Huizhen, Yao Xiaojun, Liu Huanxiang
School of Pharmacy, Lanzhou University, Lanzhou, China.
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.
Front Chem. 2021 Jul 14;9:666043. doi: 10.3389/fchem.2021.666043. eCollection 2021.
The formation of amyloid fibrils from Tau is a key pathogenic feature of Alzheimer's disease (AD). To disturb the formation of Tau aggregates is considered as a promising therapeutic strategy for AD. Recently, a natural product proanthocyanidin B2 (PB2) was confirmed to not only inhibit Tau aggregation, but also disaggregate Tau fibrils. Herein, to explore the inhibition mechanism of PB2 against Tau fibril and to provide the useful information for drug design and discovery, all-atom molecular dynamics simulations were carried out for the ordered Tau hexapeptide PHF6 oligomer in the presence and absence of PB2. The obtained result shows that PB2 can transform PHF6 oligomer from the ordered -sheet structure into disordered one. Moreover, the clustering analysis and binding free energy calculations identify that S3 site is the most potential binding site. At S3 site, by hydrophobic and hydrogen bond interactions, the residues V309, Y310 and K311 are essential for binding with PB2, especially K311. In a word, our study reveals the molecular mechanism of PB2 inhibiting PHF6 aggregation and it will provide some valuable information for the development of Tau aggregation inhibitors.
Tau蛋白形成淀粉样纤维是阿尔茨海默病(AD)的关键致病特征。干扰Tau聚集体的形成被认为是一种有前景的AD治疗策略。最近,一种天然产物原花青素B2(PB2)被证实不仅能抑制Tau聚集,还能使Tau纤维解聚。在此,为了探究PB2对Tau纤维的抑制机制,并为药物设计和发现提供有用信息,我们对有序的Tau六肽PHF6寡聚体在有和没有PB2存在的情况下进行了全原子分子动力学模拟。所得结果表明,PB2能将PHF6寡聚体从有序的β折叠结构转变为无序结构。此外,聚类分析和结合自由能计算确定S3位点是最具潜力的结合位点。在S3位点,通过疏水和氢键相互作用,残基V309、Y310和K311对于与PB2结合至关重要,尤其是K311。总之,我们的研究揭示了PB2抑制PHF6聚集的分子机制,这将为Tau聚集抑制剂的开发提供一些有价值的信息。